



2025 Oral Chemotherapy

DRUG LIST

(Formulary)

Effective July 1, 2025

This drug list includes drugs on our Commercial Formulary. For drugs included in the Value, Value Plus, Elite, or Exclusive formularies, please refer to the online formulary at [CapitalBlueCross.com](https://www.CapitalBlueCross.com).

Please note that the drugs listed below must meet the Prior Authorization (PA) criteria in order for the drug to be available at \$0 member cost sharing for where indicated.

Those drugs with an “*” after their name are designated as Specialty and are only available for a 30-day supply (which is **not** available by mail order).

This list is not a complete list. Refer to your respective formulary for a complete list at [CapitalBlueCross.com](https://www.CapitalBlueCross.com).

lowercase bold print = generic; UPPERCASE PRINT = BRAND

Drug Name

abiraterone acetate *	everolimus tablet for oral suspension *	JAKAFI *
AKEEGA	everolimus tab 2mg *	JAYPIRCA *
ALECENSA *	everolimus tab 2mg *	KISQALI *
ALKERAN	everolimus 2.5mg *	KISQALI FEMARA PAK *
ALUNBRIG *^	everolimus tab 3mg *	KOSELUGO *^
anastrozole	everolimus tab 5mg *	KRAZATI *^
ARIMIDEX	everolimus tab 5mg *	lapatinib ditosylate *
AROMASIN	everolimus tab 7.5mg *	LAZCLUZE *^
AUGTYRO *	everolimus tab 10mg *	lenalidomide **
AYVAKIT *^	exemestane	LENVIMA *
BALVERSA *^	FARESTON	letrozole
bexarotene *	FEMARA TAB 2.5MG	leucovorin calcium
bicalutamide	FOTIVDA *^	LEUKERAN
BOSULIF *	FRUZAQLA *^	LONSURF *
BRAFTOVI *	GAVRETO *^	LORBRENA *
BRUKINSA *^	gefitinib *	LUMAKRAS *
CABOMETYX *	GILOTRIF *	LYNPARZA *
CALQUENCE *^	GLEOSTINE	LYSODREN
capecitabine *	HYCAMTIN *	LYTGOBI *^
CAPRELSA *^	HYDREA	MATULANE *^
CASODEX	hydroxyurea	megestrol acetate
COMETRIQ *	IBRANCE *	MEKINIST *
COPIKTRA *^	ICLUSIG *^	MEKTOVI *
COTELLIC *	IDHIFA *	MELPHALAN
cyclophosphamide cap	imatinib mesylate *	mercaptopurine
cyclophosphamide tab	IMBRUVICA *^	mesna
dasatinib *	INLYTA *	MESNEX
DAURISMO *	INQOVI *	methotrexate sodium
EMCYT	INREBIC *	MYLERAN
ERIVEDGE *	IRESSA *	NERLYNX *
erlotinib hcl *	ITOVEBI *	NEXAVAR *

*=Specialty
^=Limited Distribution

NILANDRON	sorafenib tosylate *	TYKERB *
nilutamide	STIVARGA *	VANFLYTA *^
NINLARO *	sunitinib malate *	VENCLEXTA *^
NUBEQA *	TABLOID	VERZENIO *
ODOMZO *	TABRECTA *	VITRAKVI *
OJEMDA *^	TAFINLAR *	VIZIMPRO *
ONUREG *	TAGRISSO *	VORANIGO *^
ORGOVYX *^	TALZENNA *	VOTRIENT *
ORSERDU *^	tamoxifen citrate	WELIREG *^
pazopanib hcl *	TARGRETIN *	XALKORI *
PEMAZYRE *^	TASIGNA *	XATMEP
PIQRAY *	TAZVERIK *^	XOSPATA *^
POMALYST *	temozolomide *	XPOVIO *^
PURIXAN	TEPMETKO *^	XTANDI *
QINLOCK *^	THALOMID *	ZELBORAF *
RETEVMO *	TIBSOVO *^	ZOLINZA *
REVUFORJ *^	TOPOSAR	ZEJULA *
REZLIDHIA *^	toremifene citrate	ZYDELIG *
ROZLYTREK *	TORPENZ *^	ZYKADIA *
RUBRACA *	tretinoin	
RYDAPT *	TREXALL	
SCEMBLIX *^	TRUQAP *^	
SOLTAMOX	TUKYSA *^	
sorafenib *	TURALIO *^	

*=Specialty
^=Limited Distribution

Important notice for fully insured individual and employer group plans in Pennsylvania: Advertised health insurance policies or programs may not cover all your healthcare expenses. Read your contract or benefit booklet (certificate of coverage) carefully to determine which healthcare services are covered. Questions? Please call 800.962.2242 or the number on the back of your ID card (TTY: 711).

Healthcare benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross Blue Shield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.